Reflecting on a decade of metabolite screening and monitoring.

about

Applications of mass spectrometry in drug metabolism: 50 years of progress.Scientific or regulated validation: a tiered approach? Meeting report from a joint EBF/DVDMDG workshop.A seat at the table: the benefits of integrating bioanalytical sciences into development project teams.

P2860

Q38339664-ACB5614E-BA50-41DD-B268-2035B1A24130 Q38974603-380445D0-2DAB-4457-AFC4-21FBDC887C25 Q50653438-1F837987-CE41-4287-B4FE-EFF5129881C0

P2860

Reflecting on a decade of metabolite screening and monitoring.

Item

http://www.wikidata.org/entity/Q38195300

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Reflecting on a decade of metabolite screening and monitoring.

@en

type

Item

label

Reflecting on a decade of metabolite screening and monitoring.

@en

prefLabel

Reflecting on a decade of metabolite screening and monitoring.

@en

P1476

Reflecting on a decade of metabolite screening and monitoring.

@en

P2093

Anne-Françoise Aubry

http://www.w3.org/2001/XMLSchema#string

Giridhar Tirucherai

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Lisa J Christopher

http://www.w3.org/2001/XMLSchema#string

Mark E Arnold

http://www.w3.org/2001/XMLSchema#string

Mingshe Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data.

The significance of QT interval in drug development.

Drug metabolites in safety testing.

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.

Chiral inversion of drugs: coincidence or principle?

Enantioselective quantification of chiral drugs in human plasma with LC-MS/MS.

NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST.

Drug metabolite profiling and identification by high-resolution mass spectrometry.

Bioanalysis of drug in tissue: current status and challenges.

A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments.

P304

651-664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4155/BIO.14.19

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24620807

http://www.w3.org/2001/XMLSchema#string

Reflecting on a decade of metabolite screening and monitoring.

about

P2860

P2860

Reflecting on a decade of metabolite screening and monitoring.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698